Incyte
1801 Augustine Cutoff
Wilmington
DE
19803
United States
21 articles with Incyte
-
Incyte Announces Positive Results from a Phase 2 Study of Ruxolitinib Cream in Patients with Vitiligo
6/15/2019
Incyte announces 24-week results from its randomized, double-blind, dose-ranging, vehicle-controlled, Phase 2 study evaluating ruxolitinib cream, a nonsteroidal, anti-inflammatory, JAK inhibitor therapy, in adult patients with vitiligo.
-
Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Pemigatinib as a First-Line Therapy for Cholangiocarcinoma
6/4/2019
Cholangiocarcinoma is a cancer that arises from the cells within the bile ducts.
-
New Data from GEOMETRY mono-1 Study Show Clinically Meaningful Results in Patients with Non-Small Cell Lung Cancer with MET exon-14 Skipping Mutation Treated with Capmatinib
6/3/2019
Incyte announced primary efficacy results from the Novartis-sponsored GEOMETRY mono-1 Phase 2 clinical trial of capmatinib, an investigational, selective MET inhibitor.
-
Incyte Announces U.S. FDA Has Extended the Review Period for Ruxolitinib (Jakafi®) in Acute Graft-Versus-Host Disease
2/7/2019
Incyte announced that the U.S. Food and Drug Administration has extended the review period for the supplemental New Drug Application for ruxolitinib for the treatment of patients with acute graft-versus-host disease who have had an inadequate response to corticosteroids.
-
Incyte Appoints Christiana Stamoulis as Chief Financial Officer
1/3/2019
Incyte today announced the appointment of Christiana Stamoulis as Executive Vice President and Chief Financial Officer, effective February 11, 2019. Ms. Stamoulis will succeed David Gryska who, as planned, retired from Incyte at the end of 2018.
-
Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program for Ruxolitinib Cream in Atopic Dermatitis
12/20/2018
Incyte (Nasdaq:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-AD clinical trial program evaluating the long-term safety and efficacy of ruxolitinib cream as monotherapy for adolescent and adult patients (age ≥ 12 years) with atopic dermatitis (AD) who are candidates for topical therapy.
-
Innovent Biologics and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
12/16/2018
Incyte and Innovent Biologics, Inc. today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor).
-
Innovent and Incyte Announce Strategic Collaboration and Licensing Agreement for Three Clinical-stage Product Candidates in China
12/16/2018
Innovent Biologics, Inc. and Incyte today announced that the companies, through their respective subsidiaries, have entered into a strategic collaboration agreement for three clinical-stage product candidates discovered and developed by Incyte—pemigatinib (FGFR1/2/3 inhibitor), itacitinib (JAK1 inhibitor) and parsaclisib (PI3Kδ inhibitor).
-
Incyte Appoints Dr. Dashyant Dhanak as Chief Scientific Officer
11/27/2018
Incyte today announced the appointment of Dashyant Dhanak, Ph.D. as Executive Vice President and Chief Scientific Officer, effective December 10, 2018.
-
Multiple Abstracts Highlighting Data from Incyte’s Targeted Therapy Portfolio Accepted for Presentation at the 60th Annual ASH Meeting
11/1/2018
Results of REACH1 trial evaluating ruxolitinib (Jakafi®) in patients with steroid-refractory acute graft-versus-host disease (GVHD) accepted as an oral presentation
-
In a survey of more than 8,000 people in the biotech and pharma industry for Science, Regeneron Pharmaceuticals, topped the list.
-
FDA Grants Priority Review for Ruxolitinib (Jakafi®) as a Treatment for Patients with Acute Graft-Versus-Host Disease
10/25/2018
The FDA grants Priority Review to medicines that have the potential to provide significant improvements in the treatment of a serious disease.
-
Phase 2 GEOMETRY mono-1 Trial of Investigational Medicine Capmatinib Shows Positive Results in Patients with MET-mutated Advanced NSCLC
10/19/2018
Phase 2 study efficacy data showed overall response rate of 72.0 percent and 39.1 percent, respectively, in treatment-naive and previously treated patients with advanced MET exon-14 skipping mutated non-small cell lung cancer (NSCLC)
-
Incyte Announces Data for Pemigatinib, its Selective FGFR Inhibitor, to be Featured at the ESMO 2018 Congress
10/9/2018
Interim Phase 2 results highlight the potential of pemigatinib (INCB54828) in cholangiocarcinoma and urothelial carcinoma.
-
IMV Inc. Announces Phase 2 Basket Trial in Collaboration with Merck to Evaluate DPX-Survivac in Combination with KEYTRUDA® Across Five Solid Tumor Indications
9/11/2018
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical stage immuno-oncology corporation, today announced that it has expanded its clinical program with a Phase 2 basket trial evaluating its lead candidate, DPX-Survivac, in combination with low dose cyclophosphamide and Merck’s anti-PD-1 therapy,
-
Incyte to Present at Upcoming September 2018 Investor Conference
8/28/2018
Incyte Corporation announced today that it will present at the Morgan Stanley 16th Annual Global Healthcare Conference on Thursday, September 13, 2018 at 10:00 am EDT in New York.
-
NewLink Genetics has announced, with the company restructuring and layoffs, they are refocusing on indoximod.
-
The Loncar Cancer Immunotherapy Index has reduced the number of immunotherapy-focused companies from 30 to 25 and also swapped out a number of stocks as part of an effort to strengthen the index’s liquidity profile and ensure the holdings hold equal weight.
-
There are plenty of great scientific research stories out this week. Here’s a look at just a few of them, such as pancreas cells to cure type 1 diabetes and failed clinical trials cast doubt on new immuno-oncology targets.
-
Just about every week has plenty of exciting news in the biopharmaceutical industry, and this week was no different. Here’s a brief look back at some of our top stories.